SIGA Technologies, Inc. (OTCMKTS:SIGA)’s stock price traded up 5.3% on Monday after an insider bought additional shares in the company. The company traded as high as $5.20 and last traded at $5.19, 107,891 shares traded hands during mid-day trading. A decline of 38% from the average session volume of 175,255 shares. The stock had previously closed at $4.93.
Specifically, VP Dennis E. Hruby sold 50,000 shares of SIGA Technologies stock in a transaction on Friday, June 7th. The stock was sold at an average price of $5.61, for a total value of $280,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Paul G. Savas acquired 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The stock was purchased at an average cost of $5.08 per share, with a total value of $50,800.00. The disclosure for this purchase can be found here. Insiders own 4.71% of the company’s stock.
Separately, TheStreet lowered SIGA Technologies from a “b” rating to a “c+” rating in a report on Friday, May 10th.
The company has a 50-day moving average price of $5.38 and a 200 day moving average price of $5.73.
Institutional investors have recently made changes to their positions in the company. Nuveen Asset Management LLC purchased a new stake in shares of SIGA Technologies in the second quarter worth about $1,914,000. Jefferies Group LLC purchased a new stake in shares of SIGA Technologies in the second quarter worth about $58,000. Zebra Capital Management LLC lifted its position in shares of SIGA Technologies by 244.5% in the second quarter. Zebra Capital Management LLC now owns 55,891 shares of the biotechnology company’s stock worth $317,000 after buying an additional 39,669 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of SIGA Technologies by 5.7% in the second quarter. Vanguard Group Inc. now owns 2,681,237 shares of the biotechnology company’s stock worth $15,230,000 after buying an additional 143,831 shares in the last quarter. Finally, BlackRock Inc. lifted its position in shares of SIGA Technologies by 17.8% in the second quarter. BlackRock Inc. now owns 4,134,540 shares of the biotechnology company’s stock worth $23,485,000 after buying an additional 626,084 shares in the last quarter. Institutional investors and hedge funds own 6.66% of the company’s stock.
SIGA Technologies Company Profile (OTCMKTS:SIGA)
SIGA Technologies, Inc is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield).
Featured Article: Equal Weight Rating
Receive News & Ratings for SIGA Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SIGA Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.